title: Mediastinal radiotherapy after multidrug chemotherapy and prophylactic cranial irradiation in patients with SCLC--treatment results after long-term follow-up and literature overview.
abstract: BACKGROUND
  Curative therapy for patients with small-cell lung cancer (SCLC) is based on multidrug chemotherapy combinations and radiotherapy. After a long time follow-up, the aim of the study was to evaluate the efficacy and toxicity of sequential chemo-radiotherapy and the effect of prophylactic cranial irradiation (PCI).
  
  
  METHODS
  From 1995-2005, 96 patients with SCLC (64 limited-disease [LD], 32 extensive-disease [ED]; median age 61 years [range 39-79]) were treated at our department with varying chemotherapy regimens and sequential mediastinal radiotherapy (50 Gy + 10 Gy boost in case of residual disease after chemotherapy). Afterwards, 15 patients with LD, good general condition and at least partial response after local treatment received PCI (30 Gy).
  
  
  RESULTS
  After a median follow-up of 78.6 months, 20 patients remained alive (20.8%, median survival time 18.2 months). The 2-/5-year overall survival rates were 33.8% and 12.6%, the 2-/5-year loco-regional control rates were 30.3% and 24.5%, respectively. Distant metastases occurred in 43 patients (24 cerebral). Cerebral metastasis occurred in 6.7% and 27.2% of the patients with PCI and without PCI respectively. Only tumor stage showed a statistically significant impact on overall survival and loco-regional control in multivariate analysis. Radiotherapy was well tolerated. Grade 3/4 toxicity occurred in seven patients. Prognosis of patients with SCLC remains poor. Administration of PCI in selected patients bears a decrease in the incidence of cerebral metastases. Alternative chemotherapy schemes as well as irradiation schemes and techniques should be the substance of future randomized trials.
authors: Department of Radiotherapy, University Hospital Goettingen, Robert-Koch-Str 40, 37075 Goettingen, Germany.
authors: M K A
authors: MK
authors: Herrmann
authors: E
authors: E
authors: Bloch
authors: T
authors: T
authors: Overbeck
authors: W
authors: W
authors: Koerber
authors: H A
authors: HA
authors: Wolff
authors: A
authors: A
authors: Hille
authors: H
authors: H
authors: Vorwerk
authors: C F
authors: CF
authors: Hess
authors: M
authors: M
authors: Muller
authors: H
authors: H
authors: Christiansen
authors: O
authors: O
authors: Pradier
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000517:prevention & control* / Q000556:secondary; D003131:Combined Modality Therapy / Q000379:methods; D016371:Cranial Irradiation; D005260:Female; D005500:Follow-Up Studies; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D011879:Radiotherapy Dosage; D012074:Remission Induction; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary; D015996:Survival Rate; D055815:Young Adult
chemical_list: D006441:Hemoglobin A